Huntington’s disease (HD) is a devastating condition that has long been without a cure. However, recent research is providing renewed hope to those affected by this hereditary brain disease.
HD is characterized by progressive symptoms that affect movement, cognition, and emotions. Typically, individuals are diagnosed with HD between the ages of 30-50, and they usually live for about 15-20 years after the onset of symptoms. While the global prevalence of HD is relatively low compared to other neurodegenerative diseases like Alzheimer’s, it can have a significant impact on individuals and their families.
One of the key breakthroughs in understanding HD came in 1993 when researchers discovered that the disease is caused by repetitive expansions of three DNA letters (C, A, and G) in the Huntingtin (HTT) gene. This results in the production of a mutant huntingtin protein that leads to the characteristic symptoms of HD. The length of the repeat in the HTT gene is crucial, with repeat lengths greater than 39 leading to the development of HD.
In recent years, researchers have made significant progress in developing potential treatments for HD. One promising approach is gene therapy, such as the use of AMT-130, which aims to reduce the production of the toxic mutant huntingtin protein. Clinical trials involving HD patients have shown promising results, with slower cognitive decline and reductions in neurodegeneration markers observed after treatment.
Studies like the HD-Young Adult Study have also shed light on the early stages of HD and how cognitive deficits can manifest long before motor symptoms appear. By identifying these early markers of the disease, researchers hope to establish a treatment window that could potentially delay the onset of symptoms and improve the quality of life for individuals with the HD gene expansion.
Overall, the recent advancements in HD research offer hope for a future where effective treatments can be provided at earlier stages of the disease. By understanding the underlying mechanisms of HD and developing targeted therapies, researchers are moving closer to finding a cure for this debilitating condition.
This article was written by Barbara Jacquelyn Sahakian, Professor of Clinical Neuropsychology at the University of Cambridge, and Christelle Langley, Postdoctoral Research Associate in Cognitive Neuroscience at the University of Cambridge. It was originally published on The Conversation and has been republished under a Creative Commons license.
